Latest filings (excl ownership)
8-K
Departure of Directors or Certain Officers
20 Jun 24
DEFA14A
Additional proxy soliciting materials
10 Jun 24
10-Q
2024 Q1
Quarterly report
8 May 24
8-K
Viridian Therapeutics Highlights Recent Progress and Reports First Quarter 2024 Financial Results
8 May 24
ARS
2023 FY
Annual report to shareholders
26 Apr 24
DEFA14A
Additional proxy soliciting materials
26 Apr 24
DEF 14A
Definitive proxy
26 Apr 24
8-K
Entry into a Material Definitive Agreement
16 Apr 24
S-8
Registration of securities for employees
28 Feb 24
10-K
2023 FY
Annual report
27 Feb 24
8-K
Viridian Therapeutics Highlights Recent Progress and Reports Fourth Quarter and Full Year 2023 Financial Results
27 Feb 24
8-K
Entry into a Material Definitive Agreement
19 Jan 24
424B5
Prospectus supplement for primary offering
19 Jan 24
424B5
Prospectus supplement for primary offering
17 Jan 24
8-K
Viridian Therapeutics to Present Key 2024 Corporate Priorities at J.P. Morgan Healthcare Conference
8 Jan 24
8-K
Amendments to Articles of Incorporation or Bylaws
18 Dec 23
S-3ASR
Automatic shelf registration
30 Nov 23
10-Q
2023 Q3
Quarterly report
13 Nov 23
8-K
Viridian Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update
13 Nov 23
8-K
Departure of Directors or Certain Officers
2 Nov 23
8-K
Entry into a Material Definitive Agreement
30 Oct 23
8-K
Departure of Directors or Certain Officers
25 Sep 23
8-K
Departure of Directors or Certain Officers
12 Sep 23
S-8
Registration of securities for employees
8 Aug 23
10-Q
2023 Q2
Quarterly report
8 Aug 23
S-3ASR
Automatic shelf registration
24 Jul 23
8-K
Regulation FD Disclosure
17 Jul 23
8-K
Regulation FD Disclosure
10 Jul 23
8-K
Departure of Directors or Certain Officers
16 Jun 23
10-Q
2023 Q1
Quarterly report
10 May 23
8-K
Viridian Therapeutics Reports First Quarter 2023 Financial Results and Provides Corporate Update
9 May 23
ARS
2022 FY
Annual report to shareholders
28 Apr 23
DEFA14A
Additional proxy soliciting materials
28 Apr 23
DEF 14A
Definitive proxy
28 Apr 23
8-K
Departure of Directors or Certain Officers
12 Apr 23
S-8
Registration of securities for employees
10 Mar 23
8-K
Regulation FD Disclosure
10 Mar 23
10-K
2022 FY
Annual report
9 Mar 23
8-K
Viridian Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides
8 Mar 23
8-K
Viridian Appoints Scott Myers as President and Chief Executive Officer
6 Feb 23
Latest ownership filings
SC 13D/A
Fairmount Funds Management LLC
1 Apr 24
4
Change in insider ownership
1 Apr 24
SC 13G/A
Venrock Healthcare Capital Partners III, L.P.
14 Feb 24
SC 13G/A
Paradigm Biocapital Advisors LP
14 Feb 24
SC 13G/A
COMMODORE CAPITAL LP
14 Feb 24
3
Jennifer Tousignant
14 Feb 24
4
Jennifer Tousignant
14 Feb 24
SC 13G/A
BIOTECHNOLOGY VALUE FUND L P
14 Feb 24
SC 13G/A
Deep Track Capital, LP
14 Feb 24
SC 13G/A
VANGUARD GROUP INC
13 Feb 24
4
Thomas Ciulla
7 Feb 24
SC 13G
PERCEPTIVE ADVISORS LLC
29 Jan 24
SC 13G/A
BlackRock Inc.
29 Jan 24
4
Change in insider ownership
24 Jan 24
SC 13D/A
Fairmount Funds Management LLC
24 Jan 24
SC 13G
STATE STREET CORP
24 Jan 24
3
Thomas Ciulla
12 Jan 24
SC 13G
FMR LLC
10 Jan 24
144
Notice of proposed sale of securities
18 Dec 23
144
Notice of proposed sale of securities
12 Dec 23
SC 13G
Venrock Opportunities Fund, L.P.
8 Dec 23
144
Notice of proposed sale of securities
7 Dec 23
144
Notice of proposed sale of securities
1 Dec 23
144
Notice of proposed sale of securities
16 Nov 23
4
Seth Harmon
13 Nov 23
SC 13D/A
Fairmount Funds Management LLC
3 Nov 23
4
Change in insider ownership
1 Nov 23
3
Thomas W. Beetham
1 Nov 23
4
Thomas W. Beetham
1 Nov 23
4
Stephen F. Mahoney
1 Nov 23
3
Stephen F. Mahoney
1 Nov 23
4
Sarah Gheuens
25 Sep 23
3
Sarah Gheuens
25 Sep 23
3
Seth Harmon
19 Sep 23
4
Lara Meisner
20 Jun 23
4
Peter Evan Harwin
16 Jun 23
4
Jennifer K. Moses
16 Jun 23
4
Tomas Kiselak
16 Jun 23
4
Arlene Morris
16 Jun 23
SC 13D/A
Atlas Venture Fund VII L P
14 Jun 23